Hikma launches Epirubicin Hydrocholoride Injection, USP

Product

Hikma launches Epirubicin Hydrocholoride Injection, USP

London, 5 April 2018 – Hikma Pharmaceuticals PLC (Hikma, Group) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (rated Ba1 Moody’s / BB+ S&P, both stable) announces that its wholly-owned US subsidiary West-Ward Pharmaceuticals Corp. (West-Ward), has launched Epirubicin Hydrocholoride Injection, USP, 50mg/25mL and 200mg/100mL vials, the generic equivalent to Ellence®.

West-Ward’s Epirubicin Hydrochloride Injection, USP is indicated as a component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer.

According to IQVIA, US sales of Epirubicin Hydrochloride Injection, USP, 50mg/25mL and 200mg/100mL vials, were approximately $0.8 million in the 12 months ending January 2018.